Increasing Lexapro Dosage From 10mg To 20mg
An FDA approved medication in the treatment of major depression is Lexapro. The drug has been in use for quite some time. Like other medicines, it may have adverse events with long term use. In fact, the FDA had issued a black box warning on the drug, indicating that there is a possibility of death from the use of Lexapro. Therefore, any person contemplating its use should speak to his doctor first.
According to a recent study, Escitalopram Oxalate, a derivative of the drug escitalopram, shows effectiveness in the treatment of major depressive disorder in children and adolescents. It was found that the proportion of adverse events in Lexapro users was low (3.5% in total). The most common adverse events were restlessness (mentioned above), insomnia, and headache. The overall incidence of adverse events was similar to the proportion seen in placebo-treated patients.
This was an open-label trial comparing Lexapro with placebo. No other adverse events were reported in this study. However, several studies have now shown that the effectiveness of escitalopram can be reduced by using certain medications known as selective serotonin reuptake inhibitors (SSRIs). For example, fluoxetine is frequently prescribed to treat OCD and panic disorders, but results have shown that SSRIs are more effective in reducing the severity of OCD and other nervous system disorders.
When treating patients for major depressive disorder, the usual dosage of escitalopram is 3.0 milligrams daily. This dose is generally enough to provide relief from most of the symptoms of this condition. However, it is usually taken according to a regular schedule, usually at about seven or eight in the morning. The frequency of taking tablets should also be consistent throughout the day.
Some doctors prefer not to prescribe this drug to patients taking prescription pain relievers because of the possibility of causing severe adverse effects. It is not clear how escitalopram affects serotonin levels in the brain, especially when these drugs are already being metabolized by the liver. One theory is that when the body becomes dependent on these pills for its source of pain relief, the liver eventually stops producing the neurotransmitter serotonin. When this happens, the patient may feel anxiety, agitation, restlessness and irritability. These reactions may be related to a rise in the levels of another neurotransmitter, dopamine, which also contributes to the mood swings associated with depression.
In a placebo-controlled trial, patients taking part in a double-blind, randomized, trial, were randomly assigned to either a low dose of escitalopram or a placebo. The study concluded that there was no difference between the two in terms of effectiveness and side effects. Of note, no serious side effects were noted between the two groups. Furthermore, the data was inconclusive as compared to a recent phase 3 clinical trial evaluating the safety and efficacy of lexapro (the commercial name of escitalopram) in patients diagnosed with chronic insomnia.
Patient libido decreased 3.5% in the placebo group and the mean increase in patient libido was 3.2% in the low-dose escitalopram group.
Lexapro Immediate Effects
Other common adverse reactions were weight loss, dizziness, drowsiness, upset stomach, nausea, upset breathing, upset stomach or abdominal pain, constipation or diarrhea, and agitation. Severe problems such as allergic reactions, chest pain, allergic skin reactions or eye irritation are very rare. One case of very serious reactions was documented in which the patient’s condition deteriorated to the point that he was hospitalized and treated for pneumonia and fluid in the lungs. The problem seemed to clear up within a few days but the patient later died from complications of pneumonia. There were no signs of improvement when treated with escitalopram.
A placebo-controlled trial comparing the effects of lexapro with placebo and supratherapeutic 30 mg escitalopram showed a significant difference between the groups in terms of the number of days during which the patient had at least one panic attack. However, there were no significant differences between the groups in terms of severity of the attacks, frequency or duration. One other important point to note is that even though the participants in these trials had been given placebo medications, many did not report feeling any better or worse. There was no clear-cut evidence that either treatment had a greater effect on reducing the number or severity of panic attacks.
When looking at the effect of escitalopram on libido decreased in men, the results were less severe than the results of a placebo-controlled study where the patients received anafranil (which is known to be a drug used for erectile dysfunction). It appears that anafranil may be more effective in cases where the underlying cause of impotence is physical. Anafranil cannot be used by men with erectile dysfunction because it can be physically dangerous. Because it is an anesthetic, it is not recommended for use during surgical treatments.